Mitomycin-C for mucous membrane overgrowth in OOKP eyes

Cornea. 2014 Sep;33(9):981-4. doi: 10.1097/ICO.0000000000000183.

Abstract

Purpose: The aim of this study was to report the use of mitomycin-C (MMC) in the treatment of mucous membrane overgrowth in eyes with osteo-odonto-keratoprosthesis (OOKP).

Methods: Records of 4 cases with mucous membrane overgrowth after stage 2 OOKP surgery were reviewed.

Results: All the patients had undergone a mucous membrane trimming procedure followed by MMC application. None of the patients had any episode of recurrence of the mucous membrane overgrowth after a single application of MMC in the follow-up period that ranged from 1 to 11 years.

Conclusions: MMC can successfully arrest mucous membrane overgrowth in OOKP-implanted eyes including refractory cases.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Alkylating Agents / therapeutic use*
  • Alveolar Process / transplantation
  • Bioprosthesis*
  • Corneal Transplantation*
  • Female
  • Humans
  • Hypertrophy / drug therapy
  • Male
  • Middle Aged
  • Mitomycin / therapeutic use*
  • Mouth Mucosa / drug effects*
  • Mouth Mucosa / pathology*
  • Mouth Mucosa / transplantation
  • Stevens-Johnson Syndrome / surgery*
  • Tooth Root / transplantation

Substances

  • Alkylating Agents
  • Mitomycin